Brokerages Expect Catalent Inc (NYSE:CTLT) Will Announce Earnings of $0.24 Per Share
Wall Street analysts forecast that Catalent Inc (NYSE:CTLT) will announce earnings of $0.24 per share for the current quarter, Zacks reports. Five analysts have made estimates for Catalent’s earnings, with the lowest EPS estimate coming in at $0.18 and the highest estimate coming in at $0.35. Catalent posted earnings of $0.28 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 14.3%. The company is scheduled to announce its next quarterly earnings results before the market opens on Tuesday, November 5th.
According to Zacks, analysts expect that Catalent will report full year earnings of $1.98 per share for the current year, with EPS estimates ranging from $1.97 to $2.00. For the next financial year, analysts forecast that the company will report earnings of $2.23 per share, with EPS estimates ranging from $2.18 to $2.31. Zacks’ EPS averages are an average based on a survey of research analysts that that provide coverage for Catalent.
Catalent (NYSE:CTLT) last announced its quarterly earnings data on Tuesday, August 27th. The company reported $0.65 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.03. The firm had revenue of $725.70 million during the quarter, compared to analysts’ expectations of $719.20 million. Catalent had a return on equity of 15.89% and a net margin of 5.46%. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.67 EPS.
Shares of CTLT stock traded down $0.39 on Wednesday, reaching $48.81. The company had a trading volume of 8,260 shares, compared to its average volume of 735,490. The company has a current ratio of 2.08, a quick ratio of 1.70 and a debt-to-equity ratio of 1.71. The stock has a market cap of $7.16 billion, a PE ratio of 30.10, a PEG ratio of 2.38 and a beta of 1.70. The company has a 50-day moving average of $50.41 and a 200-day moving average of $49.57. Catalent has a 12 month low of $29.23 and a 12 month high of $58.38.
In other Catalent news, Director Gregory T. Lucier bought 2,000 shares of the business’s stock in a transaction on Monday, September 9th. The shares were acquired at an average cost of $51.64 per share, for a total transaction of $103,280.00. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO John R. Chiminski sold 97,043 shares of the stock in a transaction on Monday, October 7th. The shares were sold at an average price of $48.84, for a total value of $4,739,580.12. The disclosure for this sale can be found here. Company insiders own 1.30% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Evolution Wealth Advisors LLC purchased a new position in shares of Catalent in the 2nd quarter worth $32,000. Advisory Services Network LLC boosted its position in shares of Catalent by 115.5% during the second quarter. Advisory Services Network LLC now owns 737 shares of the company’s stock valued at $39,000 after buying an additional 395 shares during the period. Bamco Inc. NY purchased a new stake in shares of Catalent in the second quarter valued at approximately $81,000. Atria Investments LLC purchased a new stake in shares of Catalent in the second quarter valued at approximately $296,000. Finally, Point72 Hong Kong Ltd purchased a new stake in shares of Catalent in the second quarter valued at approximately $165,000.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Further Reading: What is the quiet period?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.